No. | 5-FU | PRI-2205 | TGI [%] | ILS [%] | Maximal decrease |
|---|
in body weight [%] |
|---|
5-FU | PRI-2205 | 5-FU+ | %H TGI | Effect | 5-FU | PRI-2205 | 5-FU+ | %H ILS | Effect | 5-FU | PRI-2205 | 5-FU+ |
|---|
PRI-2205 | PRI-2205 | PRI-2205 |
|---|
1 | 75 mg/kg; | 10 μg/kg | 48 | 7 | 76*
| 44 | Synergism | 21 | 2 | 77*a
| 23 | Synergism | 7 | 10 | 8 |
2 | 50 mg/kg; | 10 μg/kg | 30 | -16 | 70 | 19 | Synergism | 12 | 0 | 38*
| 12 | Synergism | 0 | 0 | 0 |
3 | 150 mg/kg; | 10 μg/kg | 87 | 25 | 96*
| 90 | Synergism | nt. | nt. | nt. | nt. | nt. | 9 | 1 | 19 |
4 | 100 mg/kg; | 5 μg/kg | 31 | -12 | 26 | 23 | Antagonism | 26 | -6 | 12 | 22 | Antagonism | 4 | 1 | 6 |
5 | 100 mg/kg; | 2.5 μg/kg | 31 | -41 | 19 | 2 | Antagonism | 26 | -15 | 32 | 16 | Synergism | 4 | 7 | 4 |
- Vitamin D analog was administered subcutaneously, three times a week.
- No. – number of experiment; TGI – tumor growth inhibition; %H TGI: hypothetical tumor growth inhibition; ILS: increase in life span; %H ILS: hypothetical increase in life span; nt.: not tested; No. 1 – TGI calculated on the 27th day of the experiment, No. 2, 4, 5 - TGI on the 30th day of the experiment; No. 3 – TGI on the 32nd day of the experiment.
- No. 1: 5-FU was injected i.p. on the first day; PRI-2205 was injected on days: 1, 3, 6, 8, 10, 13, 15, 17, 20, 22; Number of mice: control - 10; in the each treatment group - 8.
- No. 2: 5-FU was injected i.p. on days: 2, 7, 11, 16; PRI-2205 was injected on days: 2, 4, 7, 9, 11, 14, 16, 18, 21; Number of mice: control – 9, 5-FU – 8, 5-FU + PRI-2205 – 8, PRI-2205 – 7.
- No. 3: 5-FU was injected i.p. on days: 9, 16, 23; PRI-2205 was injected on days: 11, 14, 16, 18, 21, 23, 25, 28; Number of mice in each group - 8.
- No. 4 and 5: 5-FU was injected i.v. on days: 8, 15, 30, 38; PRI-2205 on days: 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 35, 37, 39, 42, 44; Number of mice: No. 4 and 5: control – 7, 5-FU – 7, PRI-2205 – 5, 5-FU + PRI-2205 – 6; *
P < 0.05 as compared to control; *a
P < 0.05 as compared to 5-FU.
